Covidien board approves company's restructuring plan

09/20/2013 | American City Business Journals

A restructuring effort that could save Covidien up to $300 million per year has been approved by the company's board, according to a regulatory filing. The plan, which includes consolidation of the company's manufacturing sites and distribution facilities, could be finalized by the close of fiscal year 2018.

View Full Article in:

American City Business Journals

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Scientist - Cell Engineering Group
San Francisco, CA
Associate Director, Compliance Business Partner I
Boehringer Ingelheim
Ridgefield, CT
U.S. DEPARTMENT OF HEALTH & HUMAN SERVICES Food and Drug Administration Office of the Chief Counsel
Silver Spring, MD, MD
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Senior Manager, Clinical Affairs - Advanced Technology
Edwards Lifesciences
Irvine, CA